DiamPark
DiamPark is a French digital health company that develops CE-marked Class I medical device software for continuous monitoring and management of Parkinson's disease, serving patients via the Digipark mobile app and healthcare professionals via the Digipark 360 dashboard, using four proprietary digital biomarkers for objective symptom tracking.
- Company typePrivate
- Founded2018
- HeadquartersChaville, France
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What DiamPark does
DiamPark is a French digital health company developing a CE-marked Class I Software as a Medical Device (SaMD) platform for the continuous monitoring and management of Parkinson's disease. The company operates a dual-product ecosystem: Digipark, a patient-facing mobile application available on iOS and Android (with Apple Watch and Wear OS integration) that captures symptoms through four proprietary digital biomarkers (Typing, Tremor, Speech, Caligraphy), a smart pillbox for medication adherence, a clinically validated symptom journal, and physiotherapy/therapeutic education content; and Digipark 360, a web-based longitudinal dashboard for neurologists and allied healthcare professionals that surfaces 3/6/12-month symptom trajectories and generates consultation summary reports. The platform is GDPR-compliant, HDS-hosted in France, and ANS-certified.
The company was founded in 2018 by Djamchid Dalili following his own Parkinson's diagnosis and was incubated at the Institut du Cerveau (ICM) in Paris from 2019-2022, which supported the scientific development of the digital biomarkers. DiamPark has obtained CE marking under EU MDR 2017/745, received a favorable HAS opinion via the AWAKENING project, and been selected for the France 2030 program. The business model is B2B2C: the patient app is distributed free via app stores (freemium model) while the professional platform Digipark 360 is positioned for institutional adoption, with a stated longer-term pathway toward French healthcare reimbursement through Article 51 experiments and HAS assessment. Strategic partners include Servier (pharma, announced Feb 2025), France Parkinson (patient association), MyBrain Technologies, and Digital Pharma Lab.
DiamPark firmographics
Firmographics- Name
- DiamPark
- Legal name
- DiamPark SAS
- Website
- https://diampark.io
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DiamPark is a French digital health company that develops CE-marked Class I medical device software for continuous monitoring and management of Parkinson's disease, serving patients via the Digipark mobile app and healthcare professionals via the Digipark 360 dashboard, using four proprietary digital biomarkers for objective symptom tracking.
- Ownership category
- akta.pro rank
DiamPark industry classification
Industry- Product category
- Digital Health Software (Neurology / Parkinson's Disease)
- NAICS
- Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Prepackaged Software (7372), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ)
- akta.pro secondary industries
- SaMD – Digital Biomarkers & Algorithmic Endpoints (HLACANAF), SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE), SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG)
Keywords
Where DiamPark is headquartered
LocationHeadquarters
- HQ city
- Chaville
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
DiamPark business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Patient Application (Digipark): The patient-facing Digipark mobile application is available for free download from Apple App Store and Google Play. Revenue model details are not publicly disclosed on the website, but the company is developing through the French healthcare reimbursement pathway (Article 51 experiments, HAS assessment), suggesting a potential future model involving health insurance coverage or national health system reimbursement.
- Healthcare Professional Platform (Digipark 360): Digipark 360 is a web-based platform for healthcare professionals. Pricing and revenue model details are not publicly disclosed. The platform enables secure data sharing with the patient's care team and provides consultation preparation tools.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free patient application with core monitoring features |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
DiamPark product offering
Product offeringCore offering
DiamPark develops and markets CE-marked Class I Software as a Medical Device (SaMD) for the continuous monitoring of Parkinson's disease. The portfolio comprises the Digipark patient mobile application (iOS/Android) for symptom journaling, medication compliance, physiotherapy exercises and smartwatch passive monitoring, and Digipark 360, a web-based clinical dashboard that gives neurologists and allied healthcare professionals longitudinal (3/6/12-month) views of patient biomarker data and auto-generated consultation reports. The platform is powered by four proprietary digital biomarkers — Typing, Tremor, Speech and Caligraphy — developed during incubation at the Institut du Cerveau (ICM).
Product overview
DiamPark offers a unified digital health ecosystem for Parkinson's disease management consisting of two primary products: Digipark (App) — a CE-marked Class I medical device mobile application for patients available on iOS and Android, and Digipark 360 — a web-based professional healthcare platform. The patient app integrates smart pillbox medication reminders, a symptom journal with clinically validated questionnaires, physiotherapy exercises, and passive smartwatch monitoring. The professional platform provides longitudinal patient dashboards with 3/6/12-month trend analysis and auto-generated consultation reports. Both products share four proprietary digital biomarkers (Typing, Tremor, Speech, Caligraphy) for objective disease tracking. An optional smartwatch integration connects with Apple Watch and Wear OS devices for continuous passive monitoring. The ecosystem also includes Motiv'Park, a therapeutic education serious game, and supports secure data sharing between patients and healthcare teams.
Differentiator
Problem solved
Functional benefit
Brands
- Digipark: Mobile application for patients with Parkinson's disease, offering smart pillbox, symptom journal, and activities & well-being features.
- Digipark 360
- Motiv'Park
Products and services
- Digipark (Patient App)
Quantifiable outcome
- Daily symptom assessments take approximately 2-5 minutes per day
- +3 more outcomes
Companies that use DiamPark
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles2 records
DiamPark technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability7 records
Feature7 records
DiamPark partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered strategic, core and supporting.
- ServierstrategicCollaboration announced February 2025 to develop innovative solutions for patients. Servier is a major French pharmaceutical company, suggesting potential integration of DiamPark's digital monitoring capabilities with Servier's Parkinson's disease treatments or clinical development programs.
- Institut du Cerveau (ICM)coreIncubated by France's largest neuroscience research center located at Pitié-Salpêtrière, Paris. The ICM incubation from 2019-2022 supported development of the four digital biomarkers (Typing, Tremor, Speech, Caligraphy) and provided scientific validation for the solution. This is a foundational partnership that enabled clinical credibility.
- MyBrain TechnologiessupportingTechnology partner contributing to the technical infrastructure or neural technology components of the DiamPark solution. Nature of partnership is technological collaboration.
- Digital Pharma LabsupportingDigital health ecosystem partner providing access to pharmaceutical industry networks and digital health expertise in France.
- France ParkinsonsupportingPatient association partner providing patient perspective, advocacy support, and access to the Parkinson's patient community in France. Key partner for patient-centered design and community outreach.
Scale indicators6 records
Recent moves8 records
Expansion highlights5 records
DiamPark competitors and assessment
Company assessmentEmerging players
- MindMaze: Digital neurotherapeutics company building software-based therapies for stroke recovery, Parkinson's, and other neurological disorders. Comparable in neuro-rehab digital therapeutic scope and consumer/clinical hardware.
- NeuroPace: Commercial-stage neuro-device company with an FDA-approved responsive neurostimulation system for epilepsy, and a Class III implanted medical device. Comparable as a neurology-focused regulated medical device with biomarker-driven care.
Regional players
- CureApp: Japan-based digital therapeutics company with reimbursed, regulatory-approved therapeutic apps (e.g., for hypertension, nicotine dependence). Comparable as a SaMD company that achieved national reimbursement for digital therapy.
Direct peers
- Click Therapeutics: Prescription digital therapeutics company with a pipeline spanning neurology and chronic disease. Comparable in SaMD business model, clinical validation approach, and pharma partnerships (e.g., Otsuka, Boehringer Ingelheim).
- MedRhythms: Digital therapeutics company focused on neurologic conditions, developing sensor-based, prescription digital therapeutics for movement disorders. Comparable as a prescription-quality SaMD targeting neurology and rehabilitation.
- Better Therapeutics: Prescription digital therapeutics company for cardiometabolic conditions. Comparable SaMD business model seeking payer reimbursement and prescription status for behavior-driven chronic disease management.
- Voluntis (Aptar Digital Health): French digital therapeutics company (now part of AptarGroup) developing companion apps for chronic disease management. Closest French/European analog with similar reimbursement, pharma partnership, and SaMD heritage.
- Akili Interactive: Digital therapeutics company with FDA-cleared prescription software for cognitive dysfunction. Comparable as a regulated SaMD targeting neurological/behavioral conditions with prescription and consumer pathways.
- Rune Labs: US-based digital health platform for Parkinson's disease using wearable data (Apple Watch) and brain imaging to inform treatment decisions. Most direct comparable: same disease focus, same hardware dependencies, and similar Strive (formerly 'Rune Study') biomarker/clinical model.
Broad incumbents
- Biofourmis: Larger RPM and digital therapeutics platform with continuous wearable-based monitoring across cardiology and chronic conditions. Comparable technology and care model, broader therapeutic scope and enterprise scale.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
DiamPark social profiles
Digital presenceDiamPark compliance and trust
Trust signalCompliance4 records
DiamPark financial estimates
Financial estimateRevenue estimate
Valuation estimate
DiamPark leadership team
Management profileNumber of profiles
Profiles2 records
DiamPark funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DiamPark M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DiamPark
What does DiamPark do?
DiamPark develops and markets CE-marked Class I Software as a Medical Device (SaMD) for the continuous monitoring of Parkinson's disease. The portfolio comprises the Digipark patient mobile application (iOS/Android) for symptom journaling, medication compliance, physiotherapy exercises and smartwatch passive monitoring, and Digipark 360, a web-based clinical dashboard that gives neurologists and allied healthcare professionals longitudinal (3/6/12-month) views of patient biomarker data and auto-generated consultation reports. The platform is powered by four proprietary digital biomarkers — Typing, Tremor, Speech and Caligraphy — developed during incubation at the Institut du Cerveau (ICM).
Is DiamPark a public or private company?
DiamPark is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was DiamPark founded?
DiamPark was founded in 2018. It employs 11 to 50 people.
Where is DiamPark based?
DiamPark is headquartered in Chaville, France, in the Europe region.
How does DiamPark make money?
Two revenue lines are on record. Patient Application (Digipark) is the primary driver. The others are healthcare Professional Platform (Digipark 360).
Who are DiamPark's main competitors?
Emerging players on record are MindMaze and NeuroPace. CureApp is listed as a regional player. Direct peers are Click Therapeutics, MedRhythms, Better Therapeutics, Voluntis (Aptar Digital Health), Akili Interactive and Rune Labs. Biofourmis is listed as a broad incumbent.
Does DiamPark have an API?
No public API is recorded for DiamPark.
What industry is DiamPark in?
DiamPark's product category is Digital Health Software (Neurology / Parkinson's Disease). Its primary akta.pro industry code is HLALAFAJ, Neurology RPM (epilepsy, Parkinson’s, MS monitoring), with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 5417 and its SIC code is 7372.